Rhumbline Advisers Buys 2,409 Shares of INmune Bio, Inc. (NASDAQ:INMB)

Rhumbline Advisers grew its stake in INmune Bio, Inc. (NASDAQ:INMB) by 14.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,153 shares of the company’s stock after acquiring an additional 2,409 shares during the period. Rhumbline Advisers’ holdings in INmune Bio were worth $150,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of INMB. Raymond James Financial Inc. bought a new position in shares of INmune Bio in the 4th quarter valued at about $2,221,000. Dauntless Investment Group LLC bought a new position in INmune Bio during the fourth quarter worth about $896,000. Millennium Management LLC grew its holdings in INmune Bio by 43.9% during the fourth quarter. Millennium Management LLC now owns 291,327 shares of the company’s stock worth $1,360,000 after purchasing an additional 88,823 shares during the period. Renaissance Technologies LLC grew its holdings in INmune Bio by 73.3% during the fourth quarter. Renaissance Technologies LLC now owns 185,800 shares of the company’s stock worth $868,000 after purchasing an additional 78,600 shares during the period. Finally, Two Sigma Investments LP grew its holdings in INmune Bio by 444.8% during the fourth quarter. Two Sigma Investments LP now owns 66,384 shares of the company’s stock worth $310,000 after purchasing an additional 54,200 shares during the period. Institutional investors own 12.72% of the company’s stock.

INmune Bio Stock Performance

INmune Bio stock opened at $7.37 on Thursday. INmune Bio, Inc. has a 52 week low of $4.32 and a 52 week high of $10.50. The stock has a market capitalization of $169.36 million, a P/E ratio of -3.82 and a beta of 1.55. The stock has a 50-day simple moving average of $7.48 and a 200 day simple moving average of $7.32.

INmune Bio (NASDAQ:INMB) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.43) EPS for the quarter, hitting analysts’ consensus estimates of ($0.43). The business had revenue of $0.05 million for the quarter. Research analysts forecast that INmune Bio, Inc. will post -2.24 earnings per share for the current year.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.